Summarized by Masters of Longevity from Longevity Technology.
A biotech update on an immunotherapy strategy for neurodegenerative disease, previewing both a clinical enrollment milestone and complementary preclinical combination data.
Key Takeaways
- Coya enrolled its 100th participant in the Phase 2/3 ALSTARS trial testing COYA 302 for ALS.
- COYA 302 combines low-dose interleukin-2 with CTLA-4 Ig and has FDA Fast Track designation.
- Preclinical mouse data showed that combining low-dose IL-2 with a GLP-1 agonist reduced brain inflammation and improved Treg-related markers.
